Nature Communications (Feb 2022)

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

  • Rana Abdelnabi,
  • Caroline S. Foo,
  • Dirk Jochmans,
  • Laura Vangeel,
  • Steven De Jonghe,
  • Patrick Augustijns,
  • Raf Mols,
  • Birgit Weynand,
  • Thanaporn Wattanakul,
  • Richard M. Hoglund,
  • Joel Tarning,
  • Charles E. Mowbray,
  • Peter Sjö,
  • Fanny Escudié,
  • Ivan Scandale,
  • Eric Chatelain,
  • Johan Neyts

DOI
https://doi.org/10.1038/s41467-022-28354-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

There is an urgent need for anti-virals targeting SARS-CoV-2. One of the most promising viral targets is the main protease of SARS-CoV-2, which is essential for viral replication and has no human analogue. Here, Abdelnabi et al. show that one of the most promising anti-virals (PF-07321332), currently in clinical trials, protects against SARS-CoV-2 alpha, beta and delta variant infection and provide evidence of reduced transmission.